• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Comparative Medicine >Long-Term Clinical Outcomes in Diabetic Rhesus Macaques (Macaca mulatta) Treated with Medroxyprogesterone Acetate for Endometriosis
【24h】

Long-Term Clinical Outcomes in Diabetic Rhesus Macaques (Macaca mulatta) Treated with Medroxyprogesterone Acetate for Endometriosis

机译：醋酸甲羟孕酮治疗糖尿病恒河猴（猕猴）的长期临床结果

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Depot medroxyprogesterone acetate (DMPA) is a common medical treatment for endometriosis in NHP. Because DMPA reportedly impairs glucoregulatory function in humans and rhesus macaques, as well as predisposes humans to diabetes mellitus (DM), we performed a retrospective study to further investigate its potential long-term clinical effects in animals with and without DM. Using a cohort of 29 rhesus macaques, we explored the hypotheses that DMPA treatment accelerates the onset of DM and that its use in rhesus macaques with endometriosis worsens clinical outcome measures (lifespan, body weight and body condition score). For both body weight and body condition score, a declining and statistically significant trend in mean values was evident as macaques developed either DM, or endometriosis or both. The addition of DMPA did not significantly alter this pattern. The presence of DM, endometriosis, or DMPA treatment statistically but not clinically significantly increased risk of death. Similarly, the presence of the 2 highly correlated variables endometriosis and DMPA treatment statistically but not clinically significantly increased the risk of incident DM. These results indicate that DMPA treatment was associated with worsening trends in lifespan and incident DM, however these trends did not achieve clinical significance in this cohort.
机译：醋酸甲羟孕酮（DMPA）库是NHP子宫内膜异位症的常用药物。因为据报道，DMPA会损害人类和恒河猴的糖调节功能，并使人类容易患糖尿病（DM），所以我们进行了一项回顾性研究，以进一步研究其在有或没有DM的动物中的潜在长期临床影响。我们使用了29个恒河猴来研究DMPA治疗会加速DM的发作，以及在患有子宫内膜异位症的恒河猴中使用DM会恶化临床结局指标（寿命，体重和身体状况评分）的假设。无论是体重还是身体状况评分，随着猕猴发展为DM或子宫内膜异位症或两者同时出现，均值的下降趋势和统计学显着趋势是显而易见的。 DMPA的添加并没有显着改变这种模式。统计学上存在DM，子宫内膜异位或DMPA治疗，但临床上并未显着增加死亡风险。类似地，统计学上但临床上不存在2个高度相关的变量子宫内膜异位症和DMPA治疗会显着增加发生DM的风险。这些结果表明DMPA治疗与寿命和DM恶化趋势相关，但是这些趋势在该队列中未达到临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号